U.S. Markets open in 3 hrs 28 mins

REFILE-FDA approves Aquestive's ALS treatment

(Refiles to add media packaging code)

Nov 22 (Reuters) - The U.S. Food and Drug Administration on Friday approved Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS).

Aquestive has developed riluzole oral film (ROF), and will market the film under the brand name Exservan. (http://bit.ly/2pIFzi5) (Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel)